RxDoctor Payments Data

Nicole Sanders

Nurse Practitioner · San Antonio, TXNPI 1386154722

Payments from drug & device makers

$3,469in general payments, 2019–2025

Across 141 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$495
  • Novartis$369
  • Merck$352
  • Bayer$348
  • Abbott$328
  • Amgen$218
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,44799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,469 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$1,440
Medicare patients
29
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$315,589
XareltoRivaroxaban93$118,622
Repatha SureclickEvolocumab69$66,265
EntrestoSacubitril/Valsartan48$41,016
FarxigaDapagliflozin Propanediol34$34,271
Praluent PenAlirocumab47$31,954
Rosuvastatin Calcium768$11,249
NexlizetBempedoic Acid/Ezetimibe18$10,988
Losartan Potassium479$6,758
Ezetimibe236$5,865
Flecainide Acetate106$4,470
Metoprolol Succinate210$3,757
Potassium Chloride155$3,551
Atorvastatin Calcium351$3,150
Amiodarone Hcl83$2,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$315,589281 claims
Johnson & JohnsonXarelto$73$118,62293 claims
NovartisEntresto$369$41,01648 claims
AstraZenecaFarxiga$92$34,27134 claims
Esperion Therapeutics, Inc.Nexlizet$88$10,98818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →